Patients should be advised to contact their GP urgently if hair loss is accompanied by scalp pain, redness, scaling, or loss of follicular openings, as these may indicate scarring alopecia requiring prompt dermatological assessment
[1] [3] [2] Regulators have described this as a very rare possible side effect, with an estimated frequency of up to 1 in 10,000 people taking semaglutide
This contrasts with some single-pathway therapies that may show diminishing returns over time due to physiological adaptation or disease progression
Reminder: BPC-157 is not an FDA-approved medical product and should not be used as a substitute for professional medical care
GLP-1 receptor agonists appear to function as neuro-metabolic modulators of reward
In others, its capacity is limited by genetics, inflammation, or scarring